Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Summary

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Timeline

Start

2023-09-12

Primary completion

2025-09

Completion

2025-11

Drugs

Indications